Lilly’s $400 Billion Surge Reshapes Big Pharma, Rally
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
An overview of the major forces behind stock index movements, with guidance on tracking catalysts and assessing risk.
21,624 articlesEli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
New Realtor.com analysis finds starter home inventory trails pre-pandemic levels by roughly 300,000 listings, with en...
February can feel like a shifting tide for the S&P 500. This guide shares how to invest smartly this month with a cle...
As the S&P 500 sits near record highs, leadership is shifting toward defensive names. This article explains why consu...
As the SaaS crowd sinks, AI-powered software names may rise to the occasion in 2026. This article explains why and po...
Intel faces execution and competition risks, but a potential anchor from Apple and sustained AI demand could keep its...
Markets are betting that rates will edge lower this year, nudging investors toward income-focused and rate-sensitive ...
Cannabis operators reported strong cash flow in 2025, but a federal tax rule still caps upside. Investors are watchin...
Decades of secrecy around cutting-edge defense programs are giving way to public scrutiny and market reassessment. In...
Two data storage stocks just flashed golden crosses, signaling momentum as AI demand tightens capacity. Here’s what i...
Amplify IDVO is delivering a 5.1% yield through a tri-source income model. This piece explains the three driving forc...